Skip to content
Politically.com Search all
Menu

2026 · 1st Quarter (Jan 1 - Mar 31)

TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS FKA TRIS

Filed by AEGIS LLC.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
1st Quarter - Report
Posted
Apr 7, 2026
Income
$50,000.00
Expenses
Not reported
Registrant
AEGIS LLC
Filing UUID
22ce7cb2-bcf5-4234-a118-ae85c3294cb8
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

ADHD treatment. Implementation of the Infrastructure Investment and Jobs Act (or bipartisan infrastructure law). Traffic safety (distracted and impaired driving). Issues related to FDA approval. Patient access to non-opioid pain medicines. NO PAIN Act implementation. H.R.1227 / S.475: Alternatives to PAIN Act. Most-Favored Nation (MFN) International reference pricing. Make America Healthy Again (MAHA) Commission.

Literal federal measure citations: H.R.1227, S.475

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.